
Investments
231Portfolio Exits
56Funds
2Service Providers
2
Want to inform investors similar to Invus Group about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Invus Group
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Invus Group in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Invus Group News
Jun 15, 2023
06/15/2023 | 02:02pm EDT Message : *Required fields NEW YORK, June 15, 2023 /PRNewswire/ -- On June 15th, CAVA Group Inc. ("Cava") (NYSE: CAVA), the category-defining Mediterranean fast-casual restaurant brand that brings heart, health, and humanity to food, began trading on NYSE, having priced its initial public offering of 14,444,444 shares at $22.00 per share. The Invus Group, LLC ("Invus"), through its affiliate Artal International S.C.A. ("Artal"), is proud to have been a partner of Cava since Cava's 2015 Series A investment round. Artal remains Cava's largest shareholder following the public offering. Invus Managing Directors Philippe Amouyal and Benjamin Felt serve on Cava's Board of Directors. "We wholeheartedly congratulate Cava's founders Ted Xenohristos, Ike Grigoropoulos, Dimitri Moshovitis, and Brett Schulman and the entire Cava team on this significant milestone and beginning of a new chapter for the company," said Felt. "We have been deeply honored to partner with Cava on their journey from a handful of restaurants to now hundreds across the United States, and we look forward to seeing Cava continue to spread the Mediterranean way in the years to come." This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Invus and Artal Invus, as exclusive investment advisor to Artal, is a global equity investment firm with an evergreen capital structure, operating out of offices in the U.S., Europe and Asia. Since its founding in 1985, Invus has focused on empowering entrepreneurs and entrepreneurial teams to transform their industries across both public and private equity investments. View original content to download multimedia: https://www.prnewswire.com/news-releases/the-invus-group-congratulates-cava-on-nyse-ipo-301852373.html SOURCE The Invus Group, LLC © PRNewswire 2023
Invus Group Investments
231 Investments
Invus Group has made 231 investments. Their latest investment was in Taysha Gene Therapies as part of their PIPE on August 8, 2023.

Invus Group Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/14/2023 | PIPE | Taysha Gene Therapies | $150M | No | 3 | |
8/9/2023 | Series C | ADARx Pharmaceuticals | $200M | Yes | Ascenta Capital, Bain Capital Life Sciences, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, TCG Crossover, Venrock Healthcare Capital Partners, and Vivo Capital | 1 |
8/3/2023 | PIPE - IV | Sensorion | $38.33M | No | 2 | |
7/31/2023 | Series A | |||||
7/13/2023 | Series C - II |
Date | 8/14/2023 | 8/9/2023 | 8/3/2023 | 7/31/2023 | 7/13/2023 |
---|---|---|---|---|---|
Round | PIPE | Series C | PIPE - IV | Series A | Series C - II |
Company | Taysha Gene Therapies | ADARx Pharmaceuticals | Sensorion | ||
Amount | $150M | $200M | $38.33M | ||
New? | No | Yes | No | ||
Co-Investors | Ascenta Capital, Bain Capital Life Sciences, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus Group, Lilly Asia Ventures, Marshall Wace Asset Management, OrbiMed Advisors, Redmile Group, SR One, T. Rowe Price, TCG Crossover, Venrock Healthcare Capital Partners, and Vivo Capital | ||||
Sources | 3 | 1 | 2 |
Invus Group Portfolio Exits
56 Portfolio Exits
Invus Group has 56 portfolio exits. Their latest portfolio exit was Neumora on September 15, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/15/2023 | IPO | Public | 4 | ||
7/18/2023 | IPO | Public | 4 | ||
7/14/2023 | Acq - Pending | 3 | |||
Date | 9/15/2023 | 7/18/2023 | 7/14/2023 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | Acq - Pending | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 4 | 4 | 3 |
Invus Group Acquisitions
3 Acquisitions
Invus Group acquired 3 companies. Their latest acquisition was Ashley Stewart on June 06, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/6/2016 | Other | $0.2M | Corporate Majority | 1 | ||
11/20/2012 | ||||||
9/30/1999 |
Date | 6/6/2016 | 11/20/2012 | 9/30/1999 |
---|---|---|---|
Investment Stage | Other | ||
Companies | |||
Valuation | |||
Total Funding | $0.2M | ||
Note | Corporate Majority | ||
Sources | 1 |
Invus Group Fund History
2 Fund Histories
Invus Group has 2 funds, including InvOpps FT1A.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/12/2018 | InvOpps FT1A | $6.73M | 1 | ||
Artal Luxembourg |
Closing Date | 6/12/2018 | |
---|---|---|
Fund | InvOpps FT1A | Artal Luxembourg |
Fund Type | ||
Status | ||
Amount | $6.73M | |
Sources | 1 |
Invus Group Service Providers
2 Service Providers
Invus Group has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Corporate Majority | Counsel | General Counsel | |
Service Provider | ||
---|---|---|
Associated Rounds | Corporate Majority | |
Provider Type | Counsel | |
Service Type | General Counsel |
Partnership data by VentureSource
Invus Group Team
15 Team Members
Invus Group has 15 team members, including current Chief Executive Officer, President, Raymond Debbane.
Name | Work History | Title | Status |
---|---|---|---|
Raymond Debbane | Chief Executive Officer, President | Current | |
Name | Raymond Debbane | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |